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Progression through the cell cycle is largely dependent on waves of periodic gene expression, and the regulatory 
networks for these transcriptome dynamics have emerged as critical points of vulnerability in various aspects of tu-
mor biology. Through RNA-sequencing of human cells during two continuous cell cycles (>2.3 billion paired reads), 
we identified over 1 000 mRNAs, non-coding RNAs and pseudogenes with periodic expression. Periodic transcripts 
are enriched in functions related to DNA metabolism, mitosis, and DNA damage response, indicating these genes 
likely represent putative cell cycle regulators. Using our set of periodic genes, we developed a new approach termed 
“mitotic trait” that can classify primary tumors and normal tissues by their transcriptome similarity to different cell 
cycle stages. By analyzing >4 000 tumor samples in The Cancer Genome Atlas (TCGA) and other expression data 
sets, we found that mitotic trait significantly correlates with genetic alterations, tumor subtype and, notably, patient 
survival. We further defined a core set of 67 genes with robust periodic expression in multiple cell types. Proteins 
encoded by these genes function as major hubs of protein-protein interaction and are mostly required for cell cycle 
progression. The core genes also have unique chromatin features including increased levels of CTCF/RAD21 binding 
and H3K36me3. Loss of these features in uterine and kidney cancers is associated with altered expression of the core 
67 genes. Our study suggests new chromatin-associated mechanisms for periodic gene regulation and offers a predic-
tor of cancer patient outcomes.
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Introduction
Eukaryotic cell division cycle requires periodic gene 
expression [1, 2]. Previous studies in yeast, mouse and 
human cells have uncovered a periodic transcriptome 
comprised of classes of messenger RNAs (mRNAs) that 
oscillate during cell cycle and regulate cell cycle progres-
sion [2-7]. In addition to mRNAs, several RNAs of other 
types were also found to be periodic, including long 
non-coding RNAs (lncRNAs) [8, 9] and short non-cod-
ing RNAs [8]. However, the prevalence of these periodic 
non-coding RNAs remains mostly unknown, as previous 
studies surveyed cell cycle-dependent transcriptomes 
using microarrays that are unable to detect these non-ca-
nonical RNA species. Furthermore, cell type-specific 
periodic transcripts have been observed across different 
cell types and related species [2, 4], suggesting distinct 
regulatory mechanisms are in place to control periodicity 
in different cellular contexts. However, the commonly 
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periodic (or cell type-independent) transcriptome is poor-
ly defined, and the mechanisms that account for cell type 
differences remain unclear.
The misregulation of cell cycle is a hallmark of cancer 
[10], however it remains unclear if specific patterns of 
periodic RNA expression across different tumor types 
bear any significance on patient outcomes or correlate 
with genetic alterations. In recent years, transcriptome 
profiling coupled with sophisticated statistical analy-
sis has enabled molecular classification of tumors into 
subtypes that correlate with patient survival and/or drug 
responses [11]. Recently, The Cancer Genome Atlas 
(TCGA) has profiled nearly 5 000 samples from >20 
tumor types for global alterations in DNA, RNA and pro-
tein [12], making it possible to analyze differences and 
similarities across a wide spectrum of tumors. Curiously, 
such molecular classifications have revealed alterations 
in common biological pathways across multiple tumor 
types [13]. Unexpected regulators of both transcription 
and chromatin structure, including histone modifiers, 
ATP-dependent chromatin remodelers and regulators of 
three-dimensional chromatin structure, were found to be 
significantly mutated in a wide-variety of cancers [14]. 
Given that periodic gene expression drives cellular divi-
sion and proliferation – major points of misregulation in 
almost all tumors – a thorough cell cycle-focused anal-
ysis of tumors should reveal additional similarities/dif-
ferences across the pan-cancer landscape and potentially 
uncover specific vulnerabilities.
We report here deep sequencing of the human tran-
scriptome through two continuous mitotic cycles fol-
lowed by comprehensive analyses. We identified a large 
number of putative cell cycle regulators that have a 
unique gene structure and high capacity for protein-pro-
tein interactions (PPIs). By analyzing over 4 000 tumors, 
we provide a new molecular classification for tumors 
based on the cell cycle-dependent transcriptome. We 
demonstrate the significance of such classifications by 
showing that specific tumor classes differ in patient 
survival times irrespective of tissue origin. Analysis of 
transcription factors and histone modifications revealed 
novel regulatory mechanisms underlying periodic gene 
expression. Finally, we identify a core set of periodic 
genes that serve as protein interaction hubs for cell cycle 
control, and further reveal the functional consequence of 
misregulation of this core gene set across different tumor 
types.
Results
Transcriptome dynamics during cell cycle
To obtain a high-resolution map of transcriptome 
dynamics during the mitotic cell cycle, we performed 
RNA-seq using synchronously dividing cells. Cells were 
synchronized by double thymidine block and collected 
every 1.5 h through two continuous divisions (~32 h), in 
which the second cycle is considered to be chemically 
unperturbed. According to cellular DNA content mea-
sured at each time point, we selected 14 samples to cover 
matched stages between the two rounds of cell division 
(Supplementary information, Figure S1A). Cell synchro-
ny was further confirmed by immunoblotting for eight 
well-known cell cycle markers (Figure 1A). From each 
sample we generated a cDNA library from poly-adenylat-
ed RNAs and performed RNA-seq with a depth of 100-
250 million paired-end reads per sample (Figure 1B). In 
total, about 2.3 billion 100-nt reads were obtained (Sup-
plementary information, Table S1) and mapped to the hu-
man genome (MapSplice, default parameters, [15]). We 
analyzed these data with Cufflinks to calculate transcript 
abundance for each gene [16]. Normalized FPKM values 
(fragments per kilobase of transcript per million mapped 
reads) were used to determine expression dynamics 
across the two cell cycles (see Materials and Methods 
section). We found that known periodic transcripts in-
cluding CCNE, CCNB1, CCNB2, and CCNA2 exhibited 
the expected expression pattern (Figure 1C), providing a 
positive control and a starting point for the identification 
of additional genes with cyclical expression patterns.
To identify periodically expressed transcripts we 
generated seven periodic seed curves with various peak 
expression timing modeled from the pattern of known 
cycling genes (Figure 1C; Supplementary information, 
Figure S1B). A simple distance metric was applied to in-
terrogate all transcripts for their similarity to each period-
ic seed curve (see Materials and Methods section). Only 
transcripts with sufficient read coverage were considered 
for this analysis (see Materials and Methods section). 
In total, we identified 1 182 periodically expressed tran-
scripts with peak expression times broadly distributed 
across all cell cycle phases (Figure 1D). Periodic genes 
were clustered according to two major peak expression 
phases (G1-S and G2-M). Consistent with prior reports 
[3], the G2-M phase had a greater number of genes (304 
in G1-S and 878 in G2-M). Interestingly, G2-M genes 
are significantly longer than those with expression peaks 
in the G1/S phase (1.8-fold, P = 7 × 10−11, Figure 1E). 
The increase in gene length tracked well with an increase 
in the total number of exons per transcript, with G2-M 
genes having about two more exons than the G1-S phase 
genes (Figure 1E). We also found that G2-M genes are 
significantly longer than all detected genes in this study 
(~8 000 well-expressed genes), while the G1-S genes are 
generally shorter than all detected genes.
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Figure 1 Periodic mRNA expression during cell cycle. (A) HeLa cells were synchronized by double-thymidine-block, released 
from the block, and collected every 1.5 h for 36 h. 14 samples were selected so that the samples from the first cell cycle 
closely matched the samples of the second cycle. Cell synchronization was confirmed by quantification of DNA content (upper 
bar graph) and immunoblotting of cell cycle markers. (B) RNA-seq reads across 14 samples aligned by inferred cell cycle 
stages. (C) Relative expression of known cell cycle transcripts from RNA-seq data and heat map representation of ideal pe-
riodic seeds extracted from the known periodic transcripts. Periodic seeds are color-coded (left bar) and row-normalized. (D) 
Heat map representing 1 182 periodic transcripts. The color bar on the left represents seven periodic seed curves to which 
the identified periodic transcripts are matched (Euclidean distance ≤ 2.5), and the right colored bar represents the general 
peak expression stages. The periodic genes were further classified as G1-S if their temporal expression patterns are similar 
to the seed curves 1-2 or as G2-M if their temporal expression patterns are similar to the seed curves 3-7 in Supplementary 
information, Figure S1B. (E) Boxplot representation of gene length (top) and number of exons (bottom) for the periodic genes. 
(F) Periodic lncRNAs represented as a heat map (top panel for 37 lncRNAs with unknown function) or as normalized expres-
sion curves for two well-known lncRNAs (bottom panel, CCNB1 is shown for reference).
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In addition to known protein coding genes, transcrip-
tome profiling by RNA-seq enabled an unbiased detec-
tion of lncRNAs, which as a class, have emerged as key 
molecules that control cell proliferation and development 
[9, 17]. To examine if the expression of lncRNAs is pe-
riodic, we mapped our reads to the annotated lncRNA 
database (http://www.broadinstitute.org/genome_bio/
human_lincrnas/). Out of ~400 lncRNAs with sufficient 
read coverage, 39 were identified as periodically ex-
pressed, including the known cell cycle-dependent ln-
cRNA, MALAT1 [18] (Figure 1F). The fact that we iden-
tified a previously reported periodic lncRNA confirms 
the sensitivity of our approach. This work represents 
the first comprehensive study of cell cycle-dependent 
expression of lncRNAs by sequencing and strongly sug-
gests that these molecules may also play important roles 
in controlling cell cycle. Further analysis of the initial 
set of 1 182 genes also revealed that ~200 of the genes 
identified in this study do not code for protein (i.e., rep-
resenting ribosomal RNAs and pseudogenes). Taken to-
gether, we identified a large set of periodically expressed 
coding and non-coding transcripts, many of which have 
never been implicated in cell division or have unknown 
functions.
Functional classification of periodic genes
We next investigated the functional gene classes found 
within the periodic transcriptome. As expected, genes in 
both groups were enriched for cell cycle-related func-
tional processes (Supplementary information, Figure 
S2A and Table S1). Specifically, genes in G1-S group 
were enriched for gene ontology (GO) terms related to 
“DNA metabolic process” (P = 6 × 10−13) and “DNA 
replication” (P = 6 × 10−14) while the G2-M group was 
highly enriched for the GO terms of “M phase” (P = 4 
× 10−34) and “organelle fission” (P = 2 × 10−31). Further 
analysis of all of the identified GO terms revealed limit-
ed overlap in specific cell cycle functions between G2-M 
and G1-S genes. The shared category included the “DNA 
damage response” and “cellular response to stress” (P < 
10−3 in both G1-S and G2-M genes), thus alluding to the 
requirement of cells to maintain genome fidelity during 
replication and mitosis. 
Using PPIs as a measure of relatedness, we uncov-
ered highly connected interaction maps in these periodic 
genes (see Materials and Methods section). The G1-S 
and G2-M genes were found in different interaction net-
works, indicating that these sets are functionally distinct 
with little co-expression overlap in dividing cells (Sup-
plementary information, Figure S2B). Clustering of these 
interaction maps revealed highly connected subclasses 
with related functions (Supplementary information, Fig-
ure S2B). We next asked whether proteins corresponding 
to periodic genes have more interaction partners than a 
background set of proteins expressed at similar levels in 
our data set. Indeed, we found that periodic genes tend 
to have more interacting partners with the G2-M genes 
having the highest number of PPIs/gene (P = 2.2 × 10−16, 
Supplementary information, Figure S2C).
Systematic analysis of periodic gene promoters
Previous studies have indicated that transcriptional 
regulation is a highly conserved mechanism that controls 
periodic gene expression and cell division [1, 2]. Classi-
cal regulators include the transcription factors E2F1 and 
FOXM1 that are required for the temporal control of gene 
expression in G1-S and G2-M stages of cell cycle, re-
spectively [4, 19-21]. Given that many of the 1 182 genes 
identified in this study have not been previously observed 
as being periodic, we sought to discover novel regula-
tory mechanisms underlying periodic gene expression. 
We first searched for motifs enriched at the promoters 
of periodic genes (see Materials and Methods section). 
We found that the promoters of the G1-S group harbored 
binding sites for cell cycle-related transcription factors 
such as E2F1, E2F4 and E2F6 motifs (Supplementary 
information, Figure S3A), while the top motifs for G2-M 
genes include binding sites for SP1, NFY, FOXO4, and 
MYC as well as unknown motifs (e.g., AACTT) that re-
semble known FOXM1-binding site [22, 23]. Additional 
motif analysis revealed a modest overlap between the 
G1-S and G2-M groups, indicating differences in regula-
tory mechanisms controlling these groups (Supplemen-
tary information, Figure S3A). The list of novel motifs 
identified with possible cognate binding proteins is shown 
in Supplementary information, Table S2.
While motif enrichment analysis suggests possible 
interactions between transcription factors and DNA 
sequence, evidence of direct protein-DNA interactions 
may strengthen these findings. To this end, we analyzed 
75 ChIP-seq (chromatin immunoprecipitaion followed 
by high-throughput sequencing) data sets performed 
in HeLa cells (ENCODE). We included transcriptional 
repressors, activators, and factors known to control cell 
cycle-dependent gene expression (see Supplementary in-
formation, Table S2). We examined ChIP signals in a 2kb 
region centered around the transcriptional start site (TSS), 
and compared promoters from G1-S or G2-M genes 
with a set of control genes with similar length and RNA 
abundance (Supplementary information, Figure S3B and 
S3C). Supporting the results of motif-based analysis, 
E2F1, E2F4 and E2F6 were significantly enriched in the 
G1-S genes, whereas FOXM1 and NFYB were enriched 
at the promoters of G2-M genes (Supplementary infor-
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mation, Figure S3A). We summarize the ChIP signals 
along with pairwise comparisons between the different 
expression phases and the associated P-values in Sup-
plementary information, Table S2. This comprehensive 
analysis has uncovered both well-known and putative 
cell cycle transcriptional regulators of the newly identi-
fied periodic genes, including an emerging regulator of 
chromatin structure, CTCF, which we study further in 
mechanistic detail. 
Analysis of regulators of chromatin structure on periodic 
genes
We identified enrichment of CTCF ChIP signals at 
the TSS of most genes, which has been observed as a 
general feature of many promoters [24]. CTCF was orig-
inally discovered as a transcriptional regulator but has 
also been shown to influence chromatin organization [25, 
26]. Intriguingly, we also identified CTCF enrichment at 
the transcription end site (TES) of the G1-S genes (but 
not the G2-M or control genes), and these G1-S gene re-
gions were co-occupied by RAD21, a component of the 
cohesin complex that has been functionally associated 
with CTCF [27] (Figure 2A). Recent evidence has also 
demonstrated that the transcriptional activator ZNF143 
co-localizes with CTCF [24, 28]. Indeed we observed 
ZNF143 co-localization with CTCF at G1-S genes with 
a modest, but significant, enrichment at the TES. Such 
chromatin architectural features are consistent with 
findings from Handoko et al. [29], where enrichment of 
CTCF was shown to coalesce actively transcribed re-
gions together into a chromatin loop. Our metagene anal-
ysis also shows that, in contrast to earlier works, CTCF 
was only present at the TES of a specific group of genes 
(Figure 2A and 2B and Supplementary information, Fig-
ure S3). Consistently, we also found a strong positive 
correlation between the presence of RAD21, CTCF and 
ZNF143 at the TES, indicating that these factors occu-
py the same regions (Figure 2C). These three proteins 
were again present at higher levels around the TES of 
G1-S genes compared with G2-M and background (Fig-
ure 2D). We also examined the TES of G1-S genes for 
enrichment of H3K4me1, a chromatin mark typically 
associated with enhancers [30], and did not observe sig-
nificant enrichment of H3K4me1 at the TES (data not 
shown). Based on these data we speculate that a unique 
distribution of chromatin architectural proteins CTCF, 
RAD21 and ZNF143 at the G1-S genes may enable gene 
loops that provide a potential mechanism for the rapid 
induction of these genes during cell cycle progression, 
a mechanism similar to the “transcriptional memory” or 
“bookmarking” for genes that undergo rapid cycles of 
activation and repression [31]. However, our results do 
not necessarily prove the existence of chromatin loops 
around G1-S genes, and further experiments are needed 
to reveal the detailed mechanism.
If CTCF is indeed critical for the activation of the 
G1-S expression wave, we would expect that this gene 
set would be deregulated in cells lacking CTCF. This 
hypothesis can be tested on a genomic scale using cancer 
genotyping data of uterine tumors (http://cbioportal.org), 
of which nearly 20% had mutations in CTCF (Figure 
2E). We analyzed gene expression data from 240 primary 
uterine tumor samples, among which 44 samples harbor 
mutations in CTCF [32]. We found that nearly ~20% 
of periodic genes were downregulated in tumors with 
mutant CTCF compared with tumors with wild type 
CTCF (Figure 2F and 2G), supporting the role of CTCF 
in mediating periodic gene expression. Altogether our 
analysis of the periodic transcriptome and the underlying 
transcription regulatory framework for the periodic genes 
reveals DNA cis-elements, transcriptional regulators and 
chromatin-associated proteins that may contribute to 
robust periodicity.
Mitotic trait classification of primary breast tissues
The features of the periodic transcriptome described 
thus far support the importance of cell cycle control in 
cancer. Since we were able to identify a transcriptional 
phenotype associated with CTCF loss in uterine cancer, 
we asked whether human tumors could be meaningfully 
classified based on their expression of periodic genes. 
We hypothesized that this periodic signature would be 
associated with the biology or clinical outcomes of hu-
man cancers. To test the feasibility of such analysis, we 
compared the expression of periodic genes between ev-
ery pair of the 14 cell cycle samples (as shown in Figure 
1) using Spearman’s rank correlation, and found a high 
degree of positive correlation between samples in the 
same stages and robust negative correlation between dif-
ferent stages (Supplementary information, Figure S4A). 
These cell cycle stage-dependent correlations were only 
observed with the periodic transcripts, as a control set 
of 1 000 arbitrarily selected transcripts or all detected 
transcripts showed no significant correlation between 
samples representing the same cell cycle stage (Supple-
mentary information, Figure S4A). This new analysis, 
referred to as “mitotic trait”, suggests that any gene 
expression data set can be compared with each of the 
14 cell cycle samples as a measure of similarity to each 
stage. We tested mitotic trait analysis against two previ-
ous microarray-based transcriptome profiling data sets, 
and found a strong correlation of same cell cycle stages 
regardless of cell type used, confirming the reliability of 
this method (Supplementary information, Figure S4B). 
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Figure 2 Novel chromatin features of periodic genes. (A) Metagene analysis of periodic genes. CTCF, RAD21, and ZNF143 
ChIP-Seq signal was plotted across background (purple), G1-S (green), and G2-M (orange). ZNF143 inset represents an en-
larged view of the transcription end site (TES). Read counts are normalized to per million mapped reads. (B) UCSC genome 
browser view of VPS18, a G1-S gene. CTCF, RAD21 and ZNF143 ChIP-seq data from ENCODE is shown at the VPS18 
locus. (C) Comparison of CTCF, RAD21, and ZNF143 at TSS and TES of the G1-S genes. Respective ChIP marks were 
summed at either the TSS (black) or TES (green) and plotted against each other. Spearman’s rank correlation is shown, and 
the significance of correlation coefficient (P-value) is calculated by t-test using non-correlation as null hypothesis. TSS was 
defined as the TSS and 1 kb upstream. TES was defined as the TES and 1 kb downstream. (D) Boxplot of TES ChIP signals. 
CTCF, RAD21, and ZNF143 ChIP signals were summed from TES to 1kb upstream and downstream in background (blue), 
G1-S (yellow), and G2-M (orange). (E) CTCF mutation frequency in and number of altered cases in tumors with gene expres-
sion data. UCEC: Uterine corpus endometrioid carcinoma; COAD: Colorectal adenocarcinoma; HNSC: Head and neck squa-
mous cell carcinoma; BLCA: Bladder urothelial carcinoma; STAD: Stomach adenocarcinoma; MED: Medulloblastoma; BRCA: 
Breast invasive carcinoma. (F) Scatterplot representation of periodic gene expression levels in uterine corpus endometrioid 
carcinoma (UCEC) tumors with CTCF mutations. Data are drawn as a function of P-value. About 20% of periodic genes (249 
genes) changed significantly in tumors (shown with a darker shade of red). (G) Boxplot representation of two G1-S genes, 
E2F1 and CCNE1, whose expression is lower in UCEC.
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This approach is similar to gene expression signatures 
that have been identified to classify tumor types [11, 13]. 
In this case, however, we used a newly generated cell 
cycle-dependent gene expression signature that measures 
the relative similarity of an expression data set to any 
cell cycle stage.
We then applied this approach to analyze data generat-
ed by TCGA [12]. We initially focused on breast cancers 
and their normal controls, since these tumors are known 
to be heterogeneous with well-annotated information on 
molecular subtypes and common mutations [33]. Mitotic 
trait analysis was carried out to compute the similarity 
of breast samples to the four major cell cycle stages, G1, 
S, G2 and M (Figure 3A). Strikingly, most normal breast 
tissues were very similar to G1 phase while tumor sam-
ples were heterogeneous in mitotic trait, consistent with 
a high degree of tumor-to-tumor variability. To further 
study this variability, we grouped breast samples accord-
ing to molecular subtypes as defined by PAM50 analysis 
[33] and found that different tumor subtypes correlated 
well with specific mitotic trait (Figure 3A). The Luminal 
A subtype was found to be more G1-like, which is con-
sistent with the fact that most of these tumors have wild 
type TP53 [33], a key factor that drives cells into senes-
cence and a G1/G0 state [34]. On the other hand, loss 
of TP53 in other subtypes correlates with an S-, G2-, or 
M- like mitotic trait. These results indicate that the clas-
sification based on mitotic trait can reliably cluster most, 
if not all, tumors and that this clustering correlates well 
specific genomic alterations. Interestingly, the published 
molecular subtype according to PAM50 has classified 
a small number of tumors as “normal-like” [33]. In our 
mitotic trait analysis, these “normal-like” tumors do not 
resemble the G1 stage like normal tissues (Figure 3A, 
shown by asterisk), suggesting that mitotic trait-based 
classification captures subtle differences in gene expres-
sion between normal and tumor-like states. Using the 
available TCGA BRCA survival data we detected a sig-
nificant difference between G1 and non-G1 like tumors.
For a more rigorous assessment of our classifications 
and survival correlations we tested whether association 
with mitotic trait classes predicted variation in patient 
survival. We evaluated microarray-based expression data 
from 1 809 breast tumors with more extensive clinical 
survival data [35]. We first hierarchically classified 
tumors based on mitotic trait and into two major groups, 
which we term the G1-like and the non-G1, and plotted 
relapse-free survival (RFS) for each group (Figure 3C). 
Again, a striking survival difference was observed; 
non-G1 tumors showed significantly shorter median 
survival times compared with the G1-like tumors 
(Figure 3C). This analysis was performed independent 
of grade or PAM50 classification suggesting that 
classification according to mitotic trait may be capable of 
independently predicting tumor prognosis.
Pan-Cancer classification of tumors by mitotic trait
Our ability to classify breast tumors based on mitotic 
trait prompted us to determine if tumors arising from 
different tissue types are amenable to this analysis and 
whether these classifications would offer predictions of 
patient outcome. Expression data from 12 tumor types 
and matched normal tissues were subjected to mitotic 
trait analysis. Based on a similarity analysis of mitotic 
trait values, we found that all, but one, normal tissue 
types strongly resembled G1 phase (Supplementary in-
formation, Figure S4C). The outlier was normal head and 
neck tissue, which resembled the M-phase. In addition, 
we observed diversity in mitotic trait classification within 
most tumor types although some were relatively homog-
enous. For example, breast tumors (as shown above), 
lung adenocarcinomas, and uterine corpus endometrioid 
carcinoma were very heterogeneous, while kidney re-
nal cell carcinoma was relatively homogenous across 
patients and most closely resembled G1. Such diversity 
may reflect meaningful tumor subtypes that are grouped 
together by histological or anatomic criteria (e.g., breast 
cancers).
Hierarchical clustering of the 12 tumor types revealed 
two major clusters of tumors: the G1-like and non-G1-
like and a third cluster that was most similar to S and M 
phases (Figure 3D). Representative tumors from each 
of the tumor types were found in both clusters with the 
exception of clear cell renal cell carcinoma (ccRCC) 
that was predominantly G1-like, indicating that the 
two major clusters represent a mixture of distinct tissue 
types. Recent efforts to classify tumors by molecular 
characteristics (e.g., mutation types or RNA expression 
levels) rather than by tissue of origin have seen some 
success in identifying subclasses [13] which may have 
implications for patient prognosis and drug responses. 
We asked whether survival differences could be observed 
in the two major classes uncovered by our mitotic trait 
analysis. Using the available survival data from 3 223 
tumors across 12 types, we found that G1-like tumors 
showed a significantly longer median overall survival 
than the non-G1 cluster (Figure 3D). Interestingly, the 
third cluster had much lower survival times than both 
G1 and non-G1. This difference was observed in spite of 
the dramatic known differences in median survival for 
different tumor types (i.e., GBM vs. KIRC) [36, 37]. To-
gether these data indicate that mitotic trait classifications 
within single tumor types (Figure 3A and 3B) or across a 
diverse set of tumors (Figure 3D) correlate with patient 
Daniel Dominguez et al.
953
www.cell-research.com | Cell Research | SPRINGER NATURE
Figure 3 Classification of human tumors by mitotic trait analysis. (A) Mitotic trait analysis of human breast tumors using the 
RNA-seq data set from TCGA. Heat map representation of the similarity between normal (n = 79) and tumor (n = 739) breast 
and four representative cell cycle stages. Significant similarity correlations are indicated by a black line on the top (see Mate-
rials and Methods section). Breast tumors were grouped together according to PAM50 molecular subtype classification [59]. 
Common genetic mutations in each tumor sample are indicated. (B) Survival analysis of breast tumors the classified by mitot-
ic trait. (C) Heat map representation of mitotic trait analysis of a distinct set of 1 809 human breast tumors clustered into two 
major classes, G1-like and non-G1 (left panel). This is from an old set of microarray analysis with matching survival results. 
Kaplan–Meier survival curves for the two major classes of breast tumors is shown (right panel). (D) Heat map representa-
tion of mitotic trait analysis of pan-cancer human tumors hierarchically clustered into two major classes (denoted by black 
or red bar). Tissue type is represented by color bar at bottom. BLCA, bladder urothelial carcinoma; BRCA, breast invasive 
carcinoma; COAD, colorectal adenocarcinoma; GBM, glioblastoma multiformae; HNSC, head and neck squamous cell car-
cinoma; KIRC, kidney renal clear cell carcinoma; LAML, acute myeloid leukemia; LUAD, lung adenocarcinoma; LUSC, lung 
squamous cell carcinoma; OV, ovarian serous cystadenocarcinoma; READ, rectum adenocarcinoma; UCEC, uterine corpus 
endometrioid carcinoma. G1-like and non-G1 (left panel). Kaplan–Meier survival curves for the three major classes of tumors 
are shown as G1, non-G1 and S + M types (right panel).
outcome and mutation status, again demarcating the im-
portance of cell cycle regulation in tumor biology.
Identification of highly functional core periodic genes
To address cell type-dependencies of periodic gene 
expression, we compared our data set with data from 
four other periodic gene expression studies in distinct 
cell lines, including foreskin fibroblasts, keratinocytes, 
osteosarcoma cells and HeLa cells. We noticed that the 
number of periodic genes shared by any two studies was 
modest, in some cases less than 30% (Supplementary 
information, Figure S5A-S5D). Possible explanations 
include differences in the method used to achieve cell 
synchrony, the type of analyses to identify periodic 
genes, the total numbers of genes initially detected, the 
platforms for expression analysis, as well as the inherent 
difference between cell types. Genes identified by oth-
er groups as periodic, but not in our analysis, exhibited 
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some periodicity, albeit the periodicity failed to meet 
our threshold (Supplementary information, Figure S5A-
S5D). The likelihood of a gene being identified across the 
different studies was most closely related to how robust 
the periodicity was for that specific gene (Supplementary 
information, Figure S5E), indicating conserved regulato-
ry mechanisms for the highly periodic genes across cell- 
and tissue- types. Furthermore, by analyzing published 
results from genome-wide RNAi screens [38-40], we 
found that a significant fraction (20-30%, P = 0.0003 by 
Fisher exact test) of periodic genes from most studies 
exhibit cell cycle-related defects after RNAi-mediated 
depletion (Supplementary information, Figure S5F), with 
the highly periodic genes being the most likely to display 
phenotypes upon depletion (Supplementary information, 
Figure S5G). These data indicate that there might be a 
“core” set of strongly periodic, cell type-independent 
genes that are functionally driving cell cycle processes.
We identified a core set of 67 genes that demonstrated 
periodicity across five different studies. We term these 
genes as “the core 67” (Figure 4A). The core 67 are 
significantly more periodic (i.e., lower periodic score, 
representing shorter distance from the seed curves) as 
compared with the total 1 182 periodic genes initially 
identified (P = 1.9 × 10−11 Supplementary information, 
Figure S5H). Interestingly, the average gene length of the 
core 67 is significantly shorter than the set of the 1 182 
periodic genes or a control set of all genes, although the 
number of exons is slightly higher in the core 67 set (Figure 
4B). Assuming constant transcription rate, this result 
suggests that the core 67 genes may be transcribed more 
rapidly, offering an explanation for their sharp increases 
in expression during cell cycle. About half of the core 
67 genes lead to cell cycle defects when depleted by 
RNAi [40], considerably more than what was observed 
for any of the periodic gene sets from five independent 
studies (Figure 4A right panel and Figure 4C). In 
addition, genes from the core 67 have more PPI partners 
than other periodic genes, forming a well-connected 
PPI network with two major clusters representing the 
G1-S and the G2-M (Figure 4D and 4E). The increased 
interactions seen for the core 67 (three fold greater PPI 
partners per gene than the total 1 182 periodic genes) 
is striking, given that these periodic genes already have 
a significantly higher number of PPIs than all detected 
genes (Figure 4D). These data suggest that the core 67 
may function as periodic regulatory hubs that control cell 
cycle progression. 
Given the unique features of the core 67, we asked 
whether these genes were misregulated in human can-
cers. To this end, we used microarray data from human 
breast tumors that have well-annotated clinical infor-
mation. We found that 86% (58 out of the 67) of genes 
in the core 67 set were associated with shorter survival 
when expressed at high levels in breast tumors (Figure 
5A-5C). Similar results were observed in ovarian and 
lung cancers (not shown). Given the possible number 
of total genes associated with the reduced survival, this 
association is significantly more than expected by chance 
(P < 4 × 10−43, hypergeometric test). Together these data 
indicate that the core 67 genes exhibit robust regulatory 
capacity across multiple cell lines and are misregulated 
in tumor samples.
The core periodic genes have unique chromatin features 
that are misregulated in cancer
To identify chromatin features common to the core 67 
genes, we analyzed the available ChIP-seq data sets for 
transcription factors, variant histones and histone modifi-
cations, and chromatin accessibility (ENCODE data sets 
as in Figure 2 and Supplementary information, Figure 
S3). We found a significant enrichment of histone modi-
fications and transcription factors associated with active 
transcription around the TSS and the gene body of the 
core 67. For example, E2F1, E2F4, RNAPII, H3K4me3, 
H3K79me2, CTCF, RAD21 and ZNF143 were enriched 
at or around the TSS of these genes (Supplementary 
information, Figure S6). As expected, we also found a 
reduction in H3K27me3 and H3K9me3, modifications 
associated with repressed genes, at these loci (Supple-
mentary information, Figure S6). Consistently, the tran-
scription-associated histone modifications, H3K36me3 
and H3K79me2, were preferentially enriched over the 
gene body (Figure 6A and 6B). Interestingly, we noticed 
that the absolute enrichment of H3K36me3 is higher 
in the core 67 as compared with either control, G1-S 
or G2-M genes. However, the increased signal was not 
associated with an increase in RNA levels (Figure 6A 
inset). This was unexpected since H3K36me3 levels gen-
erally correlate with RNA abundance.
Tri-methylation of H3K36 in human cells is catalyzed 
by the enzyme SETD2, which has emerged as a critical 
player in renal cancers [37, 41, 42]. We analyzed TC-
GA-derived RNA-seq data and found that in tumors with 
mutant SETD2, the expression levels of a subset of the 
core 67 genes were significantly higher than tumors with 
WT SETD2 (Figure 6C, two representative examples are 
shown in Figure 6D). This result is consistent with the 
observation that loss of SETD2 leads to aberrant tran-
scription initiation [43]. To correlate increased expres-
sion of these genes with patient outcome, we associated 
CDC20 and CDCA3 expression levels with survival data 
and found that patients with higher CDC20 or CDCA3 
expression had shorter event-free survival times (Fig-
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Figure 4 Features of the core cell cycle gene expression program. (A) Heat map showing the expression pattern of the core 
67 during cell cycle (left) and cognate mitocheck.org phenotypes [40] (right). (B) Average gene length (left) and number of 
exons (right) of a control set, all 1 182 periodic genes and the core 67 periodic genes. (C) Fraction of all periodic genes or the 
core 67 genes with known cell cycle defects from three independent genome-wide RNAi studies. (D) Boxplot showing the av-
erage number of interaction partners for the core 67 periodic genes. (E) Protein-protein interactions identified within the core 
67 genes grouped into the G1-S and G2-M phases. Only interactions supported by experimental evidence were used for this 
analysis.
ure 6E and 6F). In support of this observation, CDCA3 
over-expression has been associated with poor progno-
sis in oral cancers by preventing G1 phase arrest [44]. 
Thus, the identification of a core gene set with periodic 
regulation across various tissue-types in multiple studies 
revealed a common epigenetic state in these genes, and 
uncovered an unexpected association of their expression 
levels with SETD2 mutation status in kidney tumors that 
was not reported in previous TCGA analysis.
Discussion
Through massive RNA sequencing of synchronous 
cells, we generated the first comprehensive transcrip-
tome map of the cell cycle containing both coding and 
non-coding genes. We identified 1 182 periodic tran-
scripts, most of which had not been observed in previ-
ous studies. Periodic genes encode proteins with higher 
capacity for PPIs and are unique in gene structure. An 
intriguing finding was the difference in gene length 
between G1-S and G2-M genes with the G1-S genes 
being significantly shorter. This difference may reflect 
the possibility that gene length may have evolved to ac-
commodate the kinetic requirements for expression (i.e., 
rapid oscillations) during certain cell cycle stages. While 
oscillations in gene function may ultimately depend on 
the kinetics of protein synthesis, the unique structure of 
periodic genes likely contributes to temporal regulation 
of protein production. The high resolution mapping of 
transcriptome during cell cycle may also reveal addition-
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Figure 5 High expression of core periodic genes correlates with poor survival. (A, B) Two representative Kaplan–Meier plots 
shown for two of the core 67 core genes. (C) Bar graph of the log-rank P-values determined for survival differences based on 
high vs. low expression of each of the 67 core periodic genes. As shown most core periodic genes (58/67) lead to decreased 
survival when over-expressed.
al mechanisms for temporal control of gene function at 
RNA level. In support of this notion, we discovered that 
more than a thousand of genes undergo periodic splicing 
during cell cycle, resulting in oscillations of splicing 
variants that play critical roles in cell cycle progression 
[45].
We also uncovered 39 periodically expressed ln-
cRNAs, including MALAT1 which was recently shown 
to oscillate during cell cycle in lung fibroblasts [18]. 
Interestingly, loss of MALAT1 leads to the activation of 
p53 and repression of the S-phase specific transcription 
factor MYBL2, providing a possible mechanism for cell 
cycle control. In addition, NEAT1, a structural compo-
nent of para-speckles, also exhibited periodic expres-
sion, suggesting it may also have functions in cell cycle 
control. Non-coding RNAs arising from the promoter 
regions of 56 periodic genes were recently examined 
by custom microarrays [8], which led to the identifica-
tion of many putative non-coding RNAs expressed in 
a periodic fashion. However, we did not detect these 
non-coding RNAs probably due to their low expression 
levels. These findings lead us to speculate that lncRNAs 
play key roles in cell cycle control and like periodic mR-
NAs likely contribute to tumor progression. In addition 
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Figure 6 SETD2 loss alters expression of the core cell cycle gene expression program. (A, B) Metagene plot of H3K36me3 
and H3K79me2 ChIP-seq signals in a control set of genes, periodic genes and the core 67. Inset, average expression, 
FPKM, level of 67 genes compared with the background set of genes. (C) Scatterplot representation of the periodic gene 
expression levels in tumors with SETD2 mutations. Data are drawn as a function of P-value. (D) Boxplot representation of 
selected mis-regulated genes in tumors with SETD2 mutations. (E, F) Survival analysis of all kidney tumors based on the ex-
pression of CDCA3 and CDC20, members of the core 67 genes with mis-regulated expression in SETD2 mutant tumors.
to periodic changes in mRNA levels, we speculate that 
other gene-regulatory mechanisms including alternative 
splicing and alternative poly-adenylation will be period-
ic. Regulation of more than one of these gene regulatory 
steps could drastically influence protein levels during cell 
cycle.
To further understand the regulation of periodic genes 
we analyzed transcription factor binding data. As ex-
pected, E2F transcription factors were highly enriched 
at the promoters of the G1-S genes, while FOXM1 was 
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enriched at the promoters of G2-M genes. STAT3, which 
is known to drive cell cycle in the context of immune 
cell activation or specific growth factor induction, was 
also observed at the G2-M genes and may help to drive 
the expression of these mRNAs [46]. Supporting this hy-
pothesis is the data indicating that RNAi of STAT3 inhib-
its proliferation of certain tumor cells [46]. In addition to 
transcription factors, we also found CTCF and RAD21 
at the transcription start and end sites of some periodic 
genes, as well as the enrichment of certain histone mod-
ifications at or near TSS. The insulator binding protein 
CTCF has been known to position nucleosomes contain-
ing histone H2A.Z [47], a histone variant that is enriched 
around TSS during G1 phase of the cell cycle but is re-
duced at M phase [48]. Our results suggest that binding 
of CTCF happens at both TSS and transcription end site, 
and thus we speculate that CTCF enhances the period-
icity of transcripts by altering chromosome architecture 
through DNA looping, a mechanism previously observed 
in various cell types [29, 49]. Consistent with the novel 
role of CTCF in periodic gene expression, we were able 
to detect a significant decrease in the expression of 150 
periodic genes in uterine corpus endometrioid carcinoma 
with CTCF mutations.
The high-throughput transcriptome map of cell cycle 
allowed us to develop a new bioinformatic analysis, “mi-
totic trait”, to quantify the association of any gene ex-
pression data set with specific cell cycle stages. Analysis 
of breast cancer data revealed that normal breast tissue 
resembles the G1 stage while breast tumors are varied. 
Our result reiterates the transcriptome variability among 
breast cancers and suggests, as expected, that cancers 
often have deregulated cell cycle. While Whitfield et al. 
reported misregulation of periodic genes in breast can-
cer, they proposed that rapidly dividing cells may have 
increased levels of certain periodic genes [3]. An alterna-
tive possibility, and one supported by our data, is that the 
transcriptome of a tumor could resemble a specific cell 
cycle stage. Histopathological studies have shown that 
increases in the number of mitotic figures or Ki67 stain-
ing within tumor samples correlate with a decrease in 
patient survival [50, 51]. Here we found that the mitotic 
trait, which is based on gene expression at global scale, 
provides a quantitative classifier of tumors with different 
survival times. Tumors most similar to M-phase have the 
shortest survival, however it remains unclear if M-class 
tumors indeed have a higher number of cells in mitosis, 
as this information is not available. It is worth noting that 
mitotic figures estimation can be variable across studies 
[52], making it difficult to interpret survival data. How-
ever, the RNA-seq analysis used in this study has been 
standardized and employed across thousands of samples. 
Mitotic trait classes were seen not only in breast, but also 
across 12 different tumor types. All except one normal 
tissue showed high similarity to G1 phase, while clas-
sification of 12 tumors revealed that some tumor types 
are heterogeneous in mitotic trait (e.g., breast) whereas 
others are very homogenous (e.g., kidney). Importantly, 
we performed survival analysis on a mixed population 
of tumors from different tissues separated only by mitot-
ic trait and still observed differences in patient survival 
(Figure 3D). To date, most pan-cancer classifications 
have stratified tumors into the already known tissue 
types [53], whereas mitotic trait can extract prognostic 
information in a tissues-independent fashion, providing a 
valuable new criterion for tumor classification. Because 
“mitotic trait” uses independent cell cycle genes that are 
expressed in most dividing cells, this predictive signature 
may suit most tumor types. Although a reliable validation 
of new cancer classifier requires clinical data that are 
independently collected without prior biases, combining 
“mitotic trait’ with existing classifiers will likely help 
improve cancer classifications.
While nearly 4 000 genes have been labeled period-
ic in human cells by various groups, most of them are 
specific to certain cell types or experimental conditions. 
Our analysis reveals a core set of 67 genes across all 
studies using multiple cell types. The genes in this set 
have more PPIs and are shorter in length, are more likely 
to produce periodic proteins, and have severe cell cycle 
phenotypes when depleted. Further investigation of the 
epigenetic landscape revealed that H3K36me3 is en-
riched in the gene body of the core 67 genes. In addition, 
these genes were upregulated in kidney tumors that lack 
SETD2, the enzyme responsible for depositing this his-
tone mark [54]. SETD2 has been shown to be mutated 
in KIRC, and recent reports suggest that kidney tumors 
with SETD2 mutations have poor prognosis [42]. What 
is less clear is the effect of SETD2 mutations (i.e., loss 
of H3K36me3) on cell proliferation and tumors. Here 
we show that H3K36me3 is highly enriched on a set of 
genes that promote cell proliferation (Figure 6). Consis-
tently, these genes also correlated with patient outcomes 
in tumors across multiple tissues (e.g., 58/67 associated 
with shortened survival when up-regulated in breast tu-
mors), reiterating their importance irrespective of cellu-
lar context. In addition, loss of SETD2 and H3K36me3 
results in increased expression of these genes, suggesting 
that SETD2 mutations can affect tumor growth through 
mediating cell cycle regulation. Given the reported role 
of SETD2 in regulating splicing, we speculate that these 
transcripts are also mis-regulated at other gene regulatory 
steps. In sum this high-resolution map of RNA dynamics 
in cell cycle has uncovered novel features and potential 
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regulatory mechanisms for periodic gene expression and 
elucidated critical aspects of tumor biology that correlate 
with patient survival.
Materials and Methods
Cell culture, synchronizations
HeLa cells were cultured in DMEM (Gibco) medium supple-
mented with 10% FBS (Gibco). Cell cycle synchronization was 
adapted from the protocol of Whitfield et al. [3]; ~750 000 log 
phase HeLa cells were plated in 15 cm dishes in complete media 
and allowed to attach for 16 h, reaching < 30% confluence. Cells 
were subsequently treated with 2 mM thymidine (Sigma) for a total 
of 18 h, washed 2 times with 1× PBS, and supplemented with fresh 
complete media for 10 h. 2 mM thymidine was subsequently added 
for a second block of 18 h and washed as described previously.
RNA library preparations and sequencing
RNA from synchronized cells was extracted with TRIZOL 
(Invitrogen), treated with DNAse I (Qiagen), and purified on 
RNAeasy columns (Qiagen) according to the manufacturer’s pro-
tocol. RNA-seq libraries were robotically prepared with Illumina 
TruSeq Total RNA Sample Prep kits according to the manufactur-
er’s protocol and sequenced on one full flow cell of HiSeq 2000 
(Illumina), using the pair-end protocol with 100 bp read length to 
obtain eight technical sequencing replicates per sample. The RNA-
seq data reported in this paper are publically available through the 
NODE (National Omics Data Encyclopedia, http://www.biosino.
org/node/) library with the access ID: ND00000019EP.
Correlation analysis for inference of cell cycle stage (Mitotic 
Trait)
All pan-cancer data were downloaded from the TCGA Network 
(https://tcga-data.nci.nih.gov/tcga/tcgaDownload.jsp). All tumor 
samples that satisfy TCGA quality control were used in analyses 
without further filtering. Microarray data were obtained from K-M 
plot.org [35, 55]. The expression values for the 1 182 periodic 
genes were extracted from each data set to be analyzed. Before 
correlation analysis, gene expression values (RSEM values for 
TCGA data and Affymetrix gene expression values (gene-centric) 
for microarray) were normalized across all samples within the 
group. Normalization was performed in the same way as was done 
for the 14 cell cycle samples (Sample-min(Sample)/max(Sample)). 
Therefore, subsequent correlations reflect the relative similarity 
as compared with the rest of the samples within the normalization 
group. A pairwise sample to sample Spearman’s Rank comparison 
was performed across all samples including the cell cycle stages. 
For simplicity, four samples representing G1 (sample 7), S (sample 
9), G2 (sample 11) and M (sample 5) were shown in the analyses 
of cancer data. To assess the significance of the correlation, we 
carried out a permutation analysis by randomly shuffling the gene 
expression values for each tumor and calculating the correlation to 
each cell cycle stage. Permutations were carried out 1 000 times 
and the frequency in which a permutation had a better correla-
tion score was calculated. We consider an FDR of 0.1 to meet the 
significance threshold. Tumors were then subjected to hierarchal 
clustering based on their similarity profile to each cell cycle stages 
and the major resulting clusters were subsequently separated for 
survival analysis.
Survival analysis
Breast cancer survival data were collected from K-Mplot.
org [35, 55]. Pan-cancer survival data were obtained from the 
Cancer Genome Database (https://tcga-data.nci.nih.gov/tcga/
tcgaDownload.jsp) [56]. RFS was used for Kaplan–Meier plots 
for the breast cancer analysis. Time to death for Kaplan–Meier 
plots for the pan-cancer data set. All plots were drawn using the 
R version 3.1.1 survival function. For KIRC survival, K-M plots 
were generated and downloaded from cBioPortal.org. For breast 
cancer survival association with the core 67 genes (Figure 5), K-M 
were generated downloaded from K-M plotter.org [35]. To test the 
significance that 58/67 core genes correlate with patient survival. 
An assumption that 1 000 out of 8 835 (number of genes detected 
by this study) genes correlate with poor patient survival was made. 
A hypergeometric test was then performed to calculate the chance 
that if 67 genes are chosen at random from 8 835, 58 will correlate 
with poor patient survival (P = 4 × 10−43). In order for this find to 
not be statistically significant, nearly 7 000 genes would have to 
correlate with poor patient survival. Survival analysis of core 67 
genes in kidney cancer was determined by cbioportals.org survival 
plot analysis of altered genes. Altered gene expression with default 
parameters set to expression being 2 standard deviations away 
from the mean was used.
Flow cytometry and cell cycle analysis
Cells were harvested with trypsin treatment, washed 2 times in 
cold 1xPBS and subsequently fixed in 80% ice-cold ethanol for at 
least 4 h. Cells were then washed twice with 1xPBS and suspend-
ed in propidium iodide/RNase staining buffer (BD pharmingen, cat 
# 550825). Cells were analyzed by flow cytometry to count 10 000 
cells that satisfied gating criteria. Data collected were analyzed us-
ing ModFit software to discern 2N (G1), S-phase, and 4N (G2 and 
M) composition.
Mapping and filtering of RNA-seq data
The RNA-seq reads were mapped to the human genome (build 
hg19) using MapSplice informatics tool with default parameters 
[15] and transcript abundance or FPKM was assessed by Cufflinks 
[16]. Eight technical replicates were sequenced and mapped in-
dependently for cell cycle data, and we required that the standard 
deviation for eight independently assigned FPKM values to be 
no greater than 0.5 fold of average FPKM (i.e., genes with larg-
er variations between technical replicates were discarded). For 
each gene, at least 12 out of 14 cell cycle samples had to meet the 
FPKM variation criteria in order to be further analyzed. In the case 
where one or two samples did not satisfy these criteria, the final 
FPKM value for those outlier samples was adjusted to be the aver-
age of the sample before and the sample after (i.e., if gene expres-
sion of a gene in sample 5 did not meet these criteria then its gene 
expression value was adjusted to the mean of the gene expression 
of the same gene in sample 4 and 6). Finally, any gene with the 
average FPKM less than or equal to 0.5 across 14 samples was not 
further analyzed. In total 8 835 genes met our filtering criteria (i.e., 
reliably detected in HeLa cells with enough abundance for further 
statistic tests).
Identification of periodic RNAs
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For each expressed gene, we normalized its gene expression as 
follows:
 , 
                                            
where i = 1 to 8 835 for all expressed genes; n = 1 to 14 for 
the14 samples; Emin is the minimum and Emax is the maximum gene 
expression value among the 14 samples.
To identify periodic genes, normalized gene expression val-
ues (i.e., normalized (en)) for the known periodic genes, CCNB1, 
CCNA2, CCNB2, and CENPE, were used as a starting point to 
subsequently add curves with broader or sharper peaks as well as 
shifted to left or right, resulting in 7 periodic expression curves 
that cover all the phases of cell cycle (Supplementary information, 
Figure S1B). These “ideal seed curves”, which capture intermittent 
peak times and phase shifts that were not well represented within 
the initial known periodic genes. To identify genes that have sim-
ilar expression during the cell cycle time-series, we calculated the 
Euclidean Distance ED from each model seed curve to all detected 
genes as follows:
                                                                             ,
where m = 1 to 7 for all model seed curves, i = 1 to 8 835 for 
all expressed genes.
For each seed curve, we ranked the genes according to their 
ED and a cutoff of ED ≤ 2.5 was used in this study as a minimum 
requirement for periodicity (other cutoffs were also attempted, 
generating similar results). To reduce noise, we required a mini-
mum of 1.5 fold change between the Eimin and E
i
max for gene i to be 
considered periodic.
Gene ontology, protein interactions, heatmaps and promoter 
analysis
GENE-E (www.broadinstitute.org/cancer/software/GENE-E/) 
was used to generate heat maps and hierarchical clustering. Pear-
son correlations were calculated using R version 3.1.1. All heat 
maps shown are row-normalized for presentation purposes. Spear-
man’s rank correlation with average linkage was used for cluster-
ing. GO terms shown are for biological process (GOTERM_BP_
FAT) and were determined by DAVID (http://david.abcc.ncifcrf.
gov/gene2gene.jsp). To identify enriched transcription factor mo-
tifs within the promoter of periodic genes, the WEB-based Gene 
SeT AnaLysis Toolkit bioinformatics application (http://bioinfo.
vanderbilt.edu/webgestalt/) was employed using all human genes 
as background. Motifs were then converted into position weight 
matrix using TOMTOM [57]. Statistical significances were calcu-
lated with t-test, unless otherwise indicated. 
ChIP-Seq analysis
ChIP-Seq data were downloaded from ENCODE with the 
exception of FOXM1 [4]. Comparisons of ChIP-Seq signal at 
transcriptional start site (TSS), gene body, and transcriptional end 
site (TES) was conducted using ngs.plot [58]. For comparative 
analysis in the scatter plot, promoter signal was defined between 
the TSS and 1 kb upstream of the TSS. For analysis of TES signal 
was summed for the region between the TES and 1kb downstream. 
The background ChIp-seq signals were calculated by using a ran-
domly selected set of genes with matched expression levels to the 
periodic genes analyzed (shown in Supplementary information, 
Figure S3B and S3C). The significance between background and 
periodic genes was tested by two-tailed t-test, and similar results 
were observed with KS-test.
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